However, despite the uncertainties surrounding prolonged TTR knockdown, available treatments significantly improve disease outcomes in patients with ATTRv polyneuropathy or ATTR-CM compared with placebo [181,182,187]. The gene discussed is TTR; the disease is polyneuropathy.